ATE481109T1 - Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden - Google Patents

Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden

Info

Publication number
ATE481109T1
ATE481109T1 AT02773789T AT02773789T ATE481109T1 AT E481109 T1 ATE481109 T1 AT E481109T1 AT 02773789 T AT02773789 T AT 02773789T AT 02773789 T AT02773789 T AT 02773789T AT E481109 T1 ATE481109 T1 AT E481109T1
Authority
AT
Austria
Prior art keywords
antibodies
hiv
antibody fragments
nucleic acids
env
Prior art date
Application number
AT02773789T
Other languages
English (en)
Inventor
Dimiter Dimitrov
Maxime Moulard
Xiadong Xiao
Yuuei Shu
Sanjay Phogat
Mei-Yun Zhang
Dennis Burton
Original Assignee
Us Gov Health & Human Serv
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Scripps Research Inst filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE481109T1 publication Critical patent/ATE481109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02773789T 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden ATE481109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32970901P 2001-10-16 2001-10-16
PCT/US2002/033165 WO2003033666A2 (en) 2001-10-16 2002-10-16 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes

Publications (1)

Publication Number Publication Date
ATE481109T1 true ATE481109T1 (de) 2010-10-15

Family

ID=23286644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773789T ATE481109T1 (de) 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden

Country Status (7)

Country Link
US (2) US7223844B2 (de)
EP (1) EP1450857B1 (de)
AT (1) ATE481109T1 (de)
AU (1) AU2002337885B1 (de)
CA (1) CA2463931A1 (de)
DE (1) DE60237704D1 (de)
WO (1) WO2003033666A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US6951947B2 (en) 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
ATE481109T1 (de) 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP2278020A3 (de) * 2002-04-09 2011-05-11 Nationwide Children's Hospital, Inc. Antikörpergentransfer und rekombinantes AAV dafür
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US7566451B2 (en) 2002-05-06 2009-07-28 The United States Of America As Represented By The Department Of Health And Human Services Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
EP1627046A4 (de) * 2003-05-06 2008-02-13 Scripps Research Inst Bindungsmoleküle mit domänenaustausch, verwendungsverfahren und herstellungsverfahren
WO2006071206A2 (en) * 2003-09-29 2006-07-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins whith potent and broad antiviral activity
EP1735453A2 (de) 2004-03-12 2006-12-27 The Scripps Research Institute Fluoreszenz-signale abgebende biosensor-moleküle und farbstoffe in lebenden zellen zum nachweis und zur quantifizierung von protein aktivitäten
US8637234B2 (en) 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
WO2006091455A2 (en) 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP3479844B1 (de) 2005-04-15 2023-11-22 MacroGenics, Inc. Kovalente diabodies und verwendungen davon
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2616189C (en) * 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
EP2601216B1 (de) 2010-08-02 2018-01-03 MacroGenics, Inc. Kovalente diabodies und deren verwendung
MX340556B (es) * 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2811364C (en) * 2010-09-27 2022-01-04 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2741777B1 (de) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von pulmonaler hypertonie
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
CA2954168C (en) * 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
EP3080156A1 (de) * 2013-12-10 2016-10-19 F. Hoffmann-La Roche AG Verwendung der bindungsdomäne einer untereinheit einer struktur mit mehreren untereinheiten zur gezielten verabreichung pharmazeutischer wirkstoffe an die struktur mit mehreren untereinheiten
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
EP3201227A4 (de) 2014-09-29 2018-04-18 Duke University Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
MX2019007738A (es) 2016-12-27 2019-09-05 Univ Rockefeller Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
EP3762033A4 (de) * 2018-03-09 2021-12-08 Atreca, Inc. Anti-hiv-antikörper
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
WO1993015747A1 (en) 1992-02-10 1993-08-19 Progenics Pharmaceuticals, Inc. A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH08502260A (ja) 1992-09-30 1996-03-12 ザ スクリップス リサーチ インスティテュート ヒト免疫不全ウイルスに対するヒト中和モノクローナル抗体
US5925741A (en) * 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
AU680916B2 (en) 1993-05-07 1997-08-14 Biomerieux, Inc. HIV immunogenic complexes
DE69435126D1 (de) 1993-10-19 2008-10-02 Scripps Research Inst Synthetische humane neutralisierende monoklonale antikörper gegen hiv
WO1996015273A1 (en) 1994-11-10 1996-05-23 The Scripps Research Institute Method for identifying protective antigens for eliciting neutralizing antibodies
EP1717248A1 (de) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Gegen Tumoren gerichteter Vektor
US7048929B1 (en) 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
JP2003529319A (ja) 1999-01-08 2003-10-07 キャロル ディ． ウエイス， ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
DE60040136D1 (de) 1999-03-16 2008-10-16 Us Gov Nat Inst Health Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion
DK2067788T3 (da) 1999-05-18 2015-10-19 Dyax Corp Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
EP1331942A4 (de) 2000-09-22 2005-03-16 Univ Duke Immunogen mit ligandengebundenem hiv-hüllprotein
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10123041A1 (de) 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
ATE481109T1 (de) 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
US7566451B2 (en) 2002-05-06 2009-07-28 The United States Of America As Represented By The Department Of Health And Human Services Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Also Published As

Publication number Publication date
EP1450857B1 (de) 2010-09-15
EP1450857A2 (de) 2004-09-01
US20070212349A1 (en) 2007-09-13
WO2003033666A2 (en) 2003-04-24
EP1450857A4 (de) 2006-01-18
US7223844B2 (en) 2007-05-29
DE60237704D1 (de) 2010-10-28
US7378093B2 (en) 2008-05-27
AU2002337885B1 (en) 2003-04-28
US20040259075A1 (en) 2004-12-23
CA2463931A1 (en) 2003-04-24
WO2003033666A3 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
ATE481109T1 (de) Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
WO2005000244A3 (en) Methods and compositions for treating rheumatoid arthritis
EP2400021A3 (de) Verfahren und Zusammensetzungen auf ErbB3-Basis zur Behandlung von Neoplasmen
WO2003048083A3 (en) Antibodies against monocyte chemotactic proteins
AU9399501A (en) Therapeutic antibodies
WO2002058717A3 (en) Methods for treating rheumatoid arthritis using il-17 antagonists
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
EP2062917A3 (de) Antikörper für einen Erythropoetin-Rezeptor und Verwendungen damit
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
PE20071055A1 (es) Anticuerpos anti mn
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE502005006022D1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
WO2003048207A3 (en) Anti-dota antibody
WO2006026703A8 (en) Chemical compounds
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
EA200400134A1 (ru) Терапевтический агент
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2005009366A3 (en) Restoring vascular function
EP4269433A3 (de) Tgf-beta-rii-bindende proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties